Pharmaceutical companies are typically rewarded for their innovation with years of market exclusivity before cheaper generics enter the scene. But for diabetes and obesity drugs like Ozempic and ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes ...

While Novo Holdings and Catalent continue to voice ... HQ to Belgian CDMO Ardena Catalent also stressed that it believes the deal is "pro-competitive," and said that it's unaware of any ...

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a ...

(Bloomberg) -- Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up.

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Novo Nordisk is among global pharma leaders in the diabetes and weight loss segments, with indicators of continued demand and sales growth. The firm's profit margin and expected EPS growth beats ...

Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care. The company develops a long line of blockbuster glucagon-like ...

Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic.